Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IXAZOMIB Cause Progressive multifocal leukoencephalopathy? 20 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 20 reports of Progressive multifocal leukoencephalopathy have been filed in association with IXAZOMIB (NINLARO). This represents 0.1% of all adverse event reports for IXAZOMIB.

20
Reports of Progressive multifocal leukoencephalopathy with IXAZOMIB
0.1%
of all IXAZOMIB reports
17
Deaths
10
Hospitalizations

How Dangerous Is Progressive multifocal leukoencephalopathy From IXAZOMIB?

Of the 20 reports, 17 (85.0%) resulted in death, 10 (50.0%) required hospitalization, and 1 (5.0%) were considered life-threatening.

Is Progressive multifocal leukoencephalopathy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IXAZOMIB. However, 20 reports have been filed with the FAERS database.

What Other Side Effects Does IXAZOMIB Cause?

Plasma cell myeloma (3,249) Death (2,845) Off label use (2,841) Diarrhoea (2,560) Pneumonia (1,583) Nausea (1,568) Fatigue (1,456) Neuropathy peripheral (1,162) Vomiting (977) Thrombocytopenia (964)

What Other Drugs Cause Progressive multifocal leukoencephalopathy?

NATALIZUMAB (1,668) RITUXIMAB (1,647) CYCLOPHOSPHAMIDE (782) PREDNISONE (606) PREDNISOLONE (439) TACROLIMUS (438) METHOTREXATE (428) DOXORUBICIN (421) MYCOPHENOLATE MOFETIL (414) VINCRISTINE (376)

Which IXAZOMIB Alternatives Have Lower Progressive multifocal leukoencephalopathy Risk?

IXAZOMIB vs IXEKIZUMAB IXAZOMIB vs JAKAFI IXAZOMIB vs JAKAVI IXAZOMIB vs JANUMET IXAZOMIB vs JANUVIA

Related Pages

IXAZOMIB Full Profile All Progressive multifocal leukoencephalopathy Reports All Drugs Causing Progressive multifocal leukoencephalopathy IXAZOMIB Demographics